id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2017-D-5625-0015,FDA,FDA-2017-D-5625,Recommendations for Dual 510(k) and Clinical Laboratory Improvement Amendments Waiver by Application Studies; Guidance for Industry and Food and Drug Administration Staff; Availability,Notice,Notice of Data Availability,2020-02-26T05:00:00Z,2020,2,2020-02-26T05:00:00Z,,2020-02-26T15:03:25Z,2020-03859,0,0,09000064843b4ec8
FDA-2017-D-5625-0016,FDA,FDA-2017-D-5625,Recommendations for Dual 510(k) and CLIA Waiver by Application Studies Guidance for Industry and Food and Drug Administration Staff,Other,Guidance,2020-02-26T05:00:00Z,2020,2,2020-02-26T05:00:00Z,,2024-11-06T23:33:00Z,,1,0,09000064843b6329